High quality 99% Purity B7-33 100% Safe

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. RXFP1 Receptor Targeting: Binds to RXFP1 with higher affinity than native H2-relaxin, forming a complex with the angiotensin II type 2 receptor (AT2R) to enhance anti-fibrotic signaling.
2. ERK1/2 Pathway Activation: Stimulates phosphorylation of ERK1/2, upregulating matrix metalloproteinase-2 (MMP-2) expression to promote collagen degradation and reduce extracellular matrix (ECM) deposition.
3. cAMP-Independent Signaling: Unlike full-length H2-relaxin, B7-33 does not activate cAMP pathways, minimizing potential tumor-promoting effects associated with cAMP elevation.
4. Anti-Fibrotic & Anti-Inflammatory Effects: Reduces myofibroblast activation and ECM accumulation; inhibits pro-fibrotic cytokines (e.g., TGF-β1, CTGF).

3. Biological Functions & Applications

3.1 Core Physiological Effects

• Anti-Fibrotic Activity: Reduces cardiac, renal, and pulmonary fibrosis by ~50% in animal models; improves cardiac function and survival post-injury.
• Implant Compatibility: Minimizes foreign body responses; reduces fibrotic capsule thickness by nearly 50% when coated on implants (e.g., cardiac stents).
• Vascular Protection: Enhances vasodilation and reduces vascular stiffness; mitigates hypertension-related organ damage.
• Anti-Inflammatory: Inhibits pro-inflammatory cytokine release; alleviates lung inflammation in acute respiratory distress syndrome (ARDS) models.

3.2 Application Fields

4. Production & Quality Control

4.1 Manufacturing Processes

1. Solid-Phase Peptide Synthesis (SPPS): Assembles the B-chain sequence using Fmoc chemistry; purified via RP-HPLC to ≥98% purity.
2. Lyophilization: Produces stable powder; vacuum-sealed with desiccant to prevent oxidation and moisture absorption.
3. Quality Testing: Each batch undergoes identity confirmation (mass spectrometry), purity analysis (HPLC), and endotoxin screening before release.

4.2 Quality Testing Standards

5. Administration, Safety & Precautions

5.1 Administration Routes & Dosage

• Preclinical Use: Intraperitoneal (IP) injection (1–10 mg/kg/day) or subcutaneous (SC) injection (0.5–5 mg/kg/day) in animal models; local application (10–100 μM) for cell culture studies.
• Implant Coating: Coating concentration of 1–5 μg/cm² on medical devices to achieve sustained release.

5.2 Safety Profile

• Low Toxicity: No systemic toxicity reported in preclinical studies; LD₅₀ >100 mg/kg in rodents.
• Minimal Side Effects: Transient local inflammation at injection sites (≤5% incidence); no off-target organ damage observed.
• Contraindications: Hypersensitivity to B7-33 or peptide components; caution in pregnant/lactating animals (limited data).
• Drug Interactions: May enhance the efficacy of anti-fibrotic agents (e.g., pirfenidone); avoid concurrent use with RXFP1 antagonists.

5.3 Handling Guidelines

• Storage: Store at -20°C in a sealed, light-protected container; use within 1 month after reconstitution (store at 4°C).
• Transport: Cold chain transportation (2–8°C) to prevent degradation during transit.
• Research Use: Prepare fresh working solutions immediately before use; discard unused portions after 24 hours.

6. Key Advantages & Limitations

6.1 Advantages

1. Selective Signaling: Activates ERK1/2 without cAMP elevation, avoiding potential tumor-promoting effects of full-length relaxin.
2. High RXFP1 Affinity: Binds to RXFP1 with greater affinity than native H2-relaxin, enhancing anti-fibrotic efficacy.
3. Broad Anti-Fibrotic Activity: Effective in multiple organ fibrosis models (cardiac, renal, pulmonary) and implant foreign body responses.
4. Simplified Production: Single-chain structure enables cost-effective synthesis compared to full-length relaxin.

6.2 Limitations

1. Preclinical Stage: Limited clinical data; requires further studies to confirm safety and efficacy in humans.
2. Short Half-Life: Rapid clearance in vivo (plasma half-life ~30 minutes); sustained-release formulations needed for long-term therapy.
3. Route Dependency: Systemic administration requires high doses; local delivery (implant coating) is more efficient for targeted effects.